STaMINA was a phase III trial comparing progression-free survival (PFS) among 758 pts randomized to:

1. second autoHCT then lenalidomide (Len) maintenance 
2. consolidation with Len/bortezomib/ dexamethasone (RVD) followed by Len maintenance
3. Len maintenance

Long term outcomes are similar using ITT, but as treated analysis suggested a PFS benefit for tandem autoHCT, driven mainly by pts with high risk MM. Len discontinuation even at 38 mo was associated with inferior PFS.

Clinical trial information: NCT02322320